New hope for Tough-to-Treat blood cancer
NCT ID NCT03399799
Summary
This is the first study testing a new drug called talquetamab in people with advanced multiple myeloma, a type of blood cancer. The main goal is to find a safe dose and understand the drug's side effects. It is for patients whose cancer has come back or stopped responding to all other available treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, 4000, Belgium
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, 28223, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
UMCU
Utrecht, 3584 CX, Netherlands
-
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
Conditions
Explore the condition pages connected to this study.